Crinetics Pharmaceuticals consensus stays bullish, shares backed by Buy ratings

By Anna Wagner, Analysts & Consensus desk. Reviewed prior to publication on 2026-06-23, 19:06.

Crinetics Pharmaceuticals (US22663K1088) sits firmly on analysts' Buy lists today. The NASDAQ-listed biotech carries a Buy consensus from ten Wall Street analysts, who on average set their 12-month price target at around 84 US dollars per share according to recent data.

What analysts are signaling

According to an overview of Wall Street research, Crinetics Pharmaceuticals is covered by ten analysts, all of whom currently rate the stock Buy or Strong Buy, with no Hold or Sell ratings reported in the latest snapshot of estimates. Analyst consensus data on Public.com This produces a 100 percent positive recommendation profile, an unusually clear stance for a clinical-stage biotech.

The same dataset cites an average 12-month price target of 84 US dollars for Crinetics shares, implying a substantial upside against the mid-30s trading range reported on several real-time quote platforms on June 23, 2026. MarketBeat price and rating overview MarketBeat similarly shows a broadly positive analyst distribution, aligning with the Buy consensus and underlining that the stock is positioned as a growth candidate within the biotechnology peer group.

How the shares trade in the US and Europe

On the primary listing, Crinetics shares trade on the Nasdaq Global Select Market under the ticker CRNX, placing the company alongside other US biotech names rather than in a broad-market index such as the S&P 500 or NASDAQ-100. StockTITAN company and listing profile A recent snapshot shows the stock around 36 US dollars, equating to a market capitalization in the area of 3.8 billion US dollars based on data from June 23, 2026.

For European investors, Crinetics is also available as a euro-quoted line on platforms such as Tradegate and the Munich exchange, where the stock trades under the German code 6Z4 with prices in the low-30s euro range as of late June 2026. Investing.com data for CRNX and 6Z4 This dual accessibility on Nasdaq and European trading venues broadens the retail investor base beyond the US.

The pipeline behind the stock

Crinetics Pharmaceuticals focuses on small-molecule therapies for rare endocrine diseases and endocrine-related tumors, targeting G protein-coupled receptors involved in hormone regulation. StockTITAN business overview A lead program is paltusotine, commercialized under the brand PALSONIFY for acromegaly, where long-term data presented at the ENDO 2026 congress indicated durable and consistent biochemical control in treated patients.

Where the shares trade today

The Crinetics Pharmaceuticals shares (US22663K1088) most recently changed hands on Nasdaq at around 36.15 US dollars as of 2026-06-23, 10:39 Eastern Time, according to a consolidated quote, corresponding to a market capitalization of roughly 3.8 billion US dollars on that date.

This article is for informational purposes only and does not constitute investment advice, a recommendation to buy or sell any security, or any other form of financial guidance. Figures and consensus data are based on sources cited and may change over time.